We are live on ! Find out more
ABBV icon

AbbVie

2,412 hedge funds and large institutions have $121B invested in AbbVie in 2020 Q2 according to their latest regulatory filings, with 266 funds opening new positions, 1,285 increasing their positions, 672 reducing their positions, and 55 closing their positions.

New
Increased
Maintained
Reduced
Closed

384% more first-time investments, than exits

New positions opened: 266 | Existing positions closed: 55

91% more repeat investments, than reductions

Existing positions increased: 1,285 | Existing positions reduced: 672

46% more capital invested

Capital invested by funds: $82.6B → $121B (+$38.1B)

31% more funds holding in top 10

Funds holding in top 10: 150197 (+47)

8% more funds holding

Funds holding: 2,2252,412 (+187)

3.67% less ownership

Funds ownership: 73.51%69.84% (-3.7%)

13% less call options, than puts

Call options by funds: $1.85B | Put options by funds: $2.12B

Holders
2,412
Holders Change
+187
Holders Change %
+8.4%
% of All Funds
49.35%
Holding in Top 10
197
Holding in Top 10 Change
+47
Holding in Top 10 Change %
+31.33%
% of All Funds
4.03%
New
266
Increased
1,285
Reduced
672
Closed
55
Calls
$1.85B
Puts
$2.12B
Net Calls
-$274M
Net Calls Change
+$76.4M

ABBV Hedge Fund Activity: Q2 2020 in Review

2,412 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q2 2020, worth a combined $121B — up 46% from $82.6B a quarter earlier.

Buyers outnumbered sellers: 266 funds opened new ABBV positions and 55 closed out — a net gain of 211 holders — while 1,285 added to existing stakes and 672 trimmed.

The largest buyer was BlackRock, adding an estimated $1.93B. The largest seller was Arrowstreet Capital, cutting an estimated $504M.

  • 2,412 institutional investors held AbbVie (ABBV) as of Q2 2020, up from 2,225 in Q1 2020.
  • Funds reported $121B of AbbVie stock for Q2 2020, up 46% quarter-over-quarter.
  • 266 funds opened new AbbVie positions in Q2 2020 and 55 closed out, a net change of +211 holders.
  • The largest AbbVie buyer in Q2 2020 was BlackRock, an estimated $1.93B added.
  • The largest AbbVie seller in Q2 2020 was Arrowstreet Capital, an estimated $504M sold.

Based on aggregated 13F filings for Q2 2020.